Anacetrapib
Review calls anacetrapib a new weapon against dyslipidemia, pending long-term mortality data (Curr Clin Pharmacol 2011)
Original title: Anacetrapib: a new weapon against dyslipidemia
Anacetrapib is a CETP inhibitor, a new experimental drug class for treating primary hypercholesterolemia and dyslipidaemia associated with metabolic syndrome. This review highlights that, beyond its significant LDL-C lowering, anacetrapib produces a substantial increase in HDL-C, a combination the authors frame as one of its major advantages. Phase I, II, and III clinical trials had shown anacetrapib to be safe both alone and in combination with statins, but the authors note that long-term clinical trials remained necessary to establish whether the drug reduces mortality in individuals at high cardiovascular risk.
Original abstract
Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages of this agent is, apart from the significant decrease in LDL-C it produces a substantial increase in HDL-C. Phase I, II, and III clinical trials have shown that anacetrapib is safe alone or in combination with statins. However, longterm clinical trials are required in order to assess whether it reduces mortality in individuals at high-risk of cardiovascular disease.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.